This Week in Oncology — Jun 25, 2026

Welcome to This Week in Oncology. This week we're covering 8 notable papers spanning long-term outcomes in cellular immunotherapy, novel strategies to overcome resistance in solid tumors, and the biological drivers of early-onset cancer. Let's dive in.
This week's papers:
• Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas — The New England Journal of Medicine 2026 (pubmed.ncbi.nlm.nih.gov/42341302)
• Biological aging and generational shifts in early-onset cancer risk — Nature Medicine 2026 (pubmed.ncbi.nlm.nih.gov/42332142)
• Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance — Cell 2026 (pubmed.ncbi.nlm.nih.gov/42330950)
• Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer — Cancer Discovery 2026 (pubmed.ncbi.nlm.nih.gov/42329102)
• SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer — Annals of Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42323161)
• Expansion and CAR engineering of granulocyte-monocyte progenitors for cellular immunotherapy — Cell 2026 (pubmed.ncbi.nlm.nih.gov/42320470)
• Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer — Cancer Cell 2026 (pubmed.ncbi.nlm.nih.gov/42314664)
• CD4T cells impair tumor growth through IL-3 and TNF-dependent vascular damage — Science 2026 (pubmed.ncbi.nlm.nih.gov/42313973)
Listen at AudioScholar (audioscholar.cc/episode/jxzf6mm5zq)